New combo therapy shows promise for Tough-to-Treat breast cancer

NCT ID NCT04448886

First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 19 times

Summary

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a certain type of advanced breast cancer (HR+/HER2-) live longer without the disease getting worse. About 110 participants will receive either the drug alone or the combination. The goal is to see if the combo improves outcomes compared to the single drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • DF/BWCC in Clinical Affiliation with South Shore Hospital

    South Weymouth, Massachusetts, 02190, United States

  • DFCI @ Foxborough

    Foxborough, Massachusetts, 02035, United States

  • DFCI @ Milford Regional Hospital

    Milford, Massachusetts, 01757, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Emory University/Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

  • University of Pennsylvania-Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.